Angiodynamics, Inc. · NASDAQ:ANGO
Angiodynamics — 24th Annual Needham Virtual Growth Conference 2022
29 slides from Angiodynamics's conference presentation, Jan 10, 2022
Slide 1: AngioDynamics Needham Healthcare Conference
01 | 10 | 2022 ANGIODYNAMICS Needham Healthcare ConferenceJim Clemmer, President & CEO Stephen Trowbridge, EVP & CFO 1 2 Notice Regarding Forward-Looking StatementsThis presentation containsforward-looking statementswithin the meaning of the Private Securities Litigation Reform Act of 1995. All stat
Slide 2: Focused Transformation: U.S. Total Addressable Markets
3 FOCUSED TRANSFORMATION U.S. Total Addressable Markets FY2021Launch of the Auryon System gives us access to the peripheral atherectomy market $3.0B2-5% Mkt CAGR $5.5B3-7% Mkt CAGR $8.0B3-7% Mkt CAGR FY2023Planned Thrombectomy & NanoKnife System portfolio additions & new indications increase market
Slide 3: Med Device and Med Tech positioning
4 MED DEVICEMaintain Positioning Irreversible Electroporation Peripheral Atherectomy MED TECHInvest for GrowthThrombus Management
Slide 4: Thrombus Management Med Tech
THROMBUS MANAGEMENT MED TECH
Slide 5: Deep Vein Thrombosis and Pulmonary Embolism
Deep Vein Thrombosis Pulmonary Embolism PE A blood clot that forms in a deep vein, usually the leg, groin or arm A DVT breaks free from a vein wall and travels to the lungs blocking some or all of the blood supply 208,000 Iliofemoral Cases1 171,000 High-risk & intermediate-risk PE Cases1 Stages of C
Slide 6: The Difference: AngioVac System
The Difference The AngioVac System allows for the continuous aspiration of embolic material such as fresh,soft thrombi or vegetation from the venous system Utilizing a self-expanding, nitinol reinforced funnel tip Simultaneously reinfusing the patient’s own filtered bloodto limit procedural blood lo
Slide 7: Control Features for Handle & Cannula
Control Features for Handle & Cannula SYRINGE BARRELAspirate between 10 & 30cc / pull VOLUME LIMITING SWITCHAllows tailored aspiration volume VACUUM LOCKAllows for continuous aspiration When engaged in clot MANUAL ASPIRATION HANDLEControlled, single-hand design MULTIPLE TIP ANGLES00, 200, 850, 1800
Slide 8: Addressable Market: Thrombus Procedures by Location
ADDRESSABLE MARKET Thrombus Procedures by Location Right Heart/Atrium 97K Patients$77M TAMIVC/SVC – Caval DVT20K Patients$360M TAM PE167K Patients$1.6B TAM Popliteal – DVT95K Patients$300M TAM Ilio-Femoral – DVT246K Patients$700M TAM RESTORATIVE FLOW THERAPIES Funnel Tip Opening FR Size Cannula Angl
Slide 9: Thrombus Management Planned Portfolio Additions & Addressable Markets
10 THROMBUS MANAGEMENT Planned Portfolio Additions &U.S. Addressable Markets Expansion FY 2021 FY 2022 FY 2025 Q3 Q4 Q1 Q2 Q4FY 2023 Q1 Q3 Q4FY 2024 $140M $700M $3.6B $1.5B 2 (F2220, F22180)Right Atrium, Illio -caval DVT (F2220 - F22180 - F1885)Entry into Ilio-femoral DVT (F1410)Access to full Ilio-
Slide 10: Peripheral Atherectomy Med Tech
PERIPHERAL ATHERECTOMY MED TECH
Slide 11: Peripheral Atherectomy US Addressable Markets & Competitive Landscape
$600M 23%3 77%3 Over 8 Million2 Americans Suffer from P AD Over 150,000 Limbs4 are Lost Every Yearbecause of PAD 50% Mortality Rate4 Associated with PAD after Limb Loss PERIPHERAL ATHERECTOMYUS Addressable Markets & Competitive Landscape Peripheral Vascular Devices Medtech 360 Market Analysis US 201
Slide 12: Auryon System catheter sizes and laser technology
2.35 mmAspiration and Off-Center capabilities and indicated for Peripheral Atherectomy and In-Stent Restenosis (ISR) 2.0 mmAspiration capability and indicated for Peripheral Atherectomy and ISR 1.5 mmIndicated for Peripheral Atherectom y Why wavelength mattersEach type of tissue interacts differentl
Slide 13: By the Numbers
14 BY THE NUMBERS Dedicated Team Members* % Market Share** BTKBelow the Knee5,78743% 74 242 5% Lasers Placed* 13,345ISRIn Stent Restenosis1,283 10% ATKAbove the Knee6,27547% Procedures to date* * As of 01/06/2022**Peripheral Vascular Devices, Millennium Research Data 2020 based on 288K Atherectomy P
Slide 14: Technology Pipeline
Procedural Hub at all Sites of Service OBL/ASC/Hospital Technology Pipeline PAD AtherectomyCurrent Indication Arterial ThrombectomyIn Development Venous ThrombectomyIn Development Coronary AtherectomyAdjacent Expansion Opportunity Lead ExtractionAdjacent Expansion Opportunity ISR ATK BTK Acute PAD S
Slide 15: Irreversible Electroporation Med Tech
IRREVERSIBLE ELECTROPORATION MED TECH 16
Slide 16: Innovation Doctors Need
INNOVATION DOCTORS NEEDExpands treatment options and help preserve patient's quality of life DECELLULARIZATIONDestroys targeted tissue with precise treatment margins.10,11 PROBE PLACEMENTNanoKnife can be confidently used in all segments of an organ.10,11 NON-THERMALSpares vital structures by retaini
Slide 17: NanoKnife System 2021 Total Addressable Market
$1.6B 18 22%1,2 8%1,2 PROSTATE 70%1,2 2021 Total Addressable Market (TAM)PANCREAS LIVER THE NANOKNIFE SYSTEMEstimated # of US Patients Diagnosed in 20211 Liver42,230 Pancreas60,430 Prostate248,530
Slide 18: Prostate Initiative
Prostate cancer is the only solid tumor without a standardized local treatment option1Advances in genetics, imaging, and methodology support a local treatment option for PCa2But existing technology has less than ideal outcomes for cancer control and quality of life3,4 19 Approximately 100,000men are
Slide 19: PRESERVE Prostate IDE
20 PRESERVE Prostate IDE 37 SUO-CTC US sites responded to Call for Sites 20 Sites selected, focused on geographic and demographic diversity, high-volume focal therapy institutions 118 Intermediate-risk patients to be enrolled through 1-year follow up SUO-CTC is a clinical research investigator netwo
Slide 20: PRESERVE Prostate IDE
PRESERVE Prostate IDE SUO-CTC is a clinical research investigator network of 500+ members from more than 250 clinical sites in the US and Canada. 37 SUO-CTC US sites responded to Call for Sites Sites selected, focused on geographic and 20 | demographic diversity, high-volume focal therapy institutio
Slide 21: Second Quarter and YTD Highlights
SECOND QUARTER AND YTD HIGHLIGHTS Q2 FY2022 Q2 FY2021 Change YTD FY2022 YTD FY2021 Change Revenue $78,280 $72,770 7.6% $155,251 $142,986 8.6% Gross Margin 51.8% 55.2% (340 bps) 52.0% 53.1% (110 bps) Net Loss ($8,351) ($4,268) ($4,083) ($15,323) ($8,536) ($6,787) GAAP EPS ($0.21) ($0.11) ($0.10) ($0.
Slide 22: Second Quarter and YTD Highlights
24% 76% SECOND QUARTER AND YTD HIGHLIGHTS 23 Med Device Med Tech 36.4% growth 0.8% growth Q2 Revenue Growth Q2 FY21 Q2 FY22 19% 81% YTD Revenue Contribution Med Device Med Tech YTD FY21 YTD FY22 17% 83% 24% 76% 50.0% growth 0.1% growth Q2 Revenue Contribution YTD Revenue Growth 24.3 36.5 118.7 118.7
Slide 23: Second Quarter and YTD FY2022 Results
SECOND QUARTER AND YTD FY2022 RESULTS (unaudited) $ in thousands (except per share data) Q2 FY2022 Q2 FY2021 Change YTD FY2022 YTD FY2021 Change Revenue $78,280 $72,770 7.6% $155,251 $142,986 8.6% Med TechMed Device $18,886$59,394 $13,849$58,921 36.4%0.8% $36,504$118,747 $24,335$118,651 50.0%0.1% En
Slide 24: Pandemic Landscape
25 PANDEMIC LANDSCAPETaking Actions to Address Short-term Supply Chain Disruption & Long-term Ability to Supply Customers HeadwindsTight Labor MarketDrives increasing labor costsImpacts absorptionRaw Materials Inflationary PressureIncreasing Freight Costs Operational FocusIncreasing and Qualifying A
Slide 25: AngioDynamics Needham Healthcare Conference
01 | 10 | 2022 ANGIODYNAMICS Needham Healthcare ConferenceJim Clemmer, President & CEO Stephen Trowbridge, EVP & CFO 26
Slide 26: AngioDynamics Needham Healthcare Conference
ANGIODYNAMICS Needham Healthcare Conference Jim Clemmer, President & CEO Stephen Trowbridge, EVP & CFO ® angiodynamics
Slide 27: Appendix: GAAP to Non-GAAP Reconciliation
APPENDIX 27 GAAP to Non-GAAP Reconciliation 28
Slide 28: Reconciliation of GAAP to Non-GAAP
Reconciliation of GAAP to Non-GAAPNet Income (Loss) and EPS Reconciliation of Net Loss toAdjusted EBITDA (1) (2) (3) Includes costs related to merger and acquisition activities, restructurings, and unusual items, including asset impairments and write- offs, certain litigation, and other items.Adjust
Slide 29: Reconciliation of GAAP to Non-GAAP
Reconciliation of GAAP to Non-GAAP Reconciliation of Net Loss to Net Income (Loss) and EPS Adjusted EBITDA Three Months Ended Six Months Ended Three Months Ended Six Months Ended n thousands, except per shar data) Nov 30, 2021 Nov 30, 2020 Nov 30, 2021 Nov 30, 2020 Gn thousand Nov 30, 2021 Nov 30, 2
AngioDynamics — 24th Annual Needham Virtual Growth Conference 2022 on 6ix